Deorphanization strategies for dark chemical matter

Area of Science:

• Medicinal Chemistry
• Drug Discovery
• Chemical Biology

Background:

• Dark chemical matter (DCM) comprises molecules untested or inactive in numerous high-throughput screening assays.
• DCM is hypothesized to possess unique selectivity profiles, making it a promising source for novel drug candidates.
• Prioritizing DCM in screening campaigns could accelerate the discovery of highly specific therapeutic agents.

Purpose of the Study:

• To define dark chemical matter (DCM) within the context of our company's compound collection.
• To investigate the bioactivity of compounds classified as DCM using advanced profiling techniques.
• To explore the potential of DCM as a source for selective drug leads.

Main Methods:

• Definition and classification of dark chemical matter (DCM) specific to our institutional screening data.
• Application of multi-parametric profiling assays to assess the biological activity of DCM compounds.
• Comparative analysis of DCM compound activity across different research institutions.

Main Results:

• Compounds previously considered inactive (dark chemical matter) were identified and characterized.
• Multi-parametric profiling revealed subtle yet significant biological activities within the DCM pool.
• Activity of DCM compounds can be context-dependent, with some showing activity in different institutional assays while maintaining selectivity.

Conclusions:

• Dark chemical matter (DCM) represents a valuable, yet underexplored, resource in drug discovery.
• Systematic profiling of DCM can uncover novel bioactive molecules with potentially superior selectivity.
• Cross-institutional validation of DCM activity highlights the importance of assay context in drug discovery.